determin
whether
immunolog
pharmaceut
product
potenti
therapi
treat
multipl
sclerosi
ms
detail
anim
model
requir
date
mani
anim
model
human
ms
describ
mice
rat
rabbit
guinea
pig
marmoset
rhesu
monkey
comprehens
studi
involv
murin
experiment
allerg
autoimmun
encephalomyel
eae
semliki
forest
viru
sfv
mous
hepat
viru
mhv
theiler
murin
encephalomyel
viru
tmev
describ
detail
multispeci
anim
model
human
ms
name
eae
sfv
mhv
tmev
addit
chemic
induc
demyelin
valid
applic
model
critic
evalu
multipl
sclerosi
ms
affect
peopl
unit
state
major
caus
nervou
system
disabl
adult
age
year
symptom
divers
rang
tremor
nystagmu
paralysi
disturb
speech
vision
extens
demyelin
seen
neuron
lesion
clinic
heterogen
ms
well
find
differ
patholog
pattern
suggest
ms
may
spectrum
diseas
may
repres
differ
patholog
process
led
develop
mani
differ
anim
model
includ
rodent
nonhuman
primat
reflect
patholog
process
could
allow
develop
therapeut
approach
present
time
exact
etiolog
mechan
human
clear
howev
sever
anim
model
avail
provid
insight
diseas
process
rel
inaccess
sensit
central
nervou
system
cn
human
preclud
studi
diseas
pathogenesi
much
understand
infect
immun
respons
deriv
experiment
anim
model
experiment
system
includ
theiler
viru
mous
hepat
viru
semliki
forest
viru
infect
laboratori
rodent
addit
inform
obtain
studi
experiment
infect
anim
result
demyelin
notabl
maedivisna
viru
sheep
canin
distemp
viru
dog
human
anim
natur
case
demyelin
diseas
rare
complic
viral
infect
one
possibl
reason
low
incid
demyelin
follow
viral
infect
could
low
effici
neuroinvas
howev
correl
cn
infect
clinic
diseas
difficult
determin
role
genet
environment
factor
ms
complex
factor
geograph
locat
ethnic
background
cluster
temper
climat
contribut
suscept
individu
north
european
heritag
statist
suscept
ms
tropic
environ
common
women
epidemiolog
data
indic
ms
singlegen
disord
addit
environment
factor
contribut
diseas
data
genet
studi
indic
although
mhc
gene
clearli
contribut
diseas
suscept
andor
resist
probabl
combin
environment
factor
may
addit
contribut
diseas
develop
genet
predispos
individu
understand
initi
factor
progress
ms
research
turn
experiment
model
system
sinc
diseas
recreat
tissu
cultur
system
much
effort
direct
use
laboratori
anim
anim
model
mirror
clinic
patholog
fi
nding
observ
human
ms
ideal
anim
model
speci
easi
handl
inexpens
kept
larg
number
easili
bred
laboratori
condit
frequent
use
anim
laboratori
rodent
includ
mice
rat
guinea
pig
hamster
one
use
aspect
laboratori
rodent
anim
model
diseas
vast
array
inbr
strain
speci
avail
notabl
experiment
mice
addit
valuabl
inform
obtain
studi
use
larger
anim
includ
sheep
dog
cat
nonhuman
primat
model
ms
fall
two
main
group
viral
nonvir
viral
model
immens
relev
sinc
epidemiolog
studi
suggest
environment
factor
almost
natur
occur
cn
demyelin
diseas
human
anim
known
etiolog
caus
viru
includ
human
subacut
scleros
panenceph
sspe
caus
measl
rubella
virus
progress
multifoc
leukoencephalopathi
pml
caus
jc
viru
human
lymphotroph
associ
myelopathi
ham
caus
anim
includ
visna
viru
sheep
canin
distemp
dog
howev
one
viru
consist
associ
human
ms
although
like
one
viru
could
trigger
diseas
nonvir
model
ms
experiment
allerg
encephalomyel
eae
wide
studi
eae
character
inflammatori
infiltr
cn
associ
demyelin
lesion
eae
diseas
initi
extraneur
inject
cn
materi
purifi
myelin
compon
emulsifi
adjuv
commonli
employ
one
complet
freund
adjuv
contain
mycobacterium
tuberculosi
howev
natur
occur
autoimmun
correl
experiment
diseas
known
although
extens
research
model
ms
reason
ms
may
diseas
wide
studi
model
ms
experiment
infect
rodent
result
inflammatori
demyelin
diseas
cn
theiler
viru
mous
hepat
viru
semliki
forest
viru
infect
give
rise
lesion
mononuclear
cell
inflammatori
demyelin
throughout
brain
spinal
cord
peripher
nervou
system
histopatholog
correl
human
ms
although
preclud
fact
virus
could
gain
access
cn
via
peripher
nervou
system
viral
model
demonstr
viru
easili
reproduc
cn
diseas
compar
rare
human
influenc
mani
factor
includ
genet
immunolog
experiment
studi
induc
anim
model
advantag
studi
spontan
model
onset
progress
diseas
control
although
propos
autoimmun
diseas
may
viral
etiolog
virusinduc
autoimmun
controversi
subject
epidemiolog
studi
ms
provid
strong
evid
involv
viral
etiolog
onset
diseas
theiler
virusinduc
demyelin
model
human
ms
bear
sever
similar
human
diseas
immunemedi
demyelin
involv
helper
cell
cytotox
cell
delay
type
hypersensit
respons
viral
antigen
autoantigen
patholog
inde
mous
model
may
provid
scenario
close
resembl
chronic
progress
ms
theiler
murin
encephalomyel
viru
tmev
picornaviru
caus
asymptomat
gastrointestin
infect
follow
occasion
paralysi
two
main
strain
tmev
virul
strain
persist
theiler
origin
strain
virul
gdvii
strain
theiler
viru
highli
neurovirul
inject
intracrani
caus
death
enceph
within
h
gdvii
strain
also
caus
differ
form
paralysi
depend
rout
inocul
see
tabl
studi
appear
gdvii
viru
may
gain
access
cn
retrograd
axon
transport
rather
hematogen
rout
infect
suscept
strain
mice
persist
strain
bean
da
ww
yale
result
primari
demyelin
diseas
close
resembl
human
ms
infect
resist
strain
mice
bean
result
demyelin
diseas
sinc
mice
abl
clear
viru
cn
suscept
mice
fail
clear
viru
cn
possibl
result
poor
natur
killer
nk
cell
cytotox
lymphocyt
ctl
respons
persist
viral
infect
cn
requir
demyelin
follow
intracrani
inject
suscept
mice
bean
viru
replic
brain
spinal
cord
one
month
postinfect
viral
titer
decreas
high
level
neutral
antibodi
detect
figur
point
diseas
neuron
may
becom
infect
viru
mice
may
develop
nonprogress
flaccid
paralysi
forelimb
andor
hindlimb
sometim
refer
poliolik
diseas
confus
sinc
flaccid
paralysi
mice
infect
polioviru
progress
normal
result
death
late
phase
diseas
astrocyt
oligodendrocyt
macrophagemicrogli
cell
becom
infect
viru
also
demyelin
diseas
b
cell
autoimmun
direct
myelin
antigen
compon
genet
persist
infect
demyelin
diseas
inbr
mous
strain
inocul
intracerebr
tmev
show
earli
encephalomyel
strain
remain
persist
infect
resist
strain
normal
trait
multigen
control
mhc
class
gene
promin
addit
sever
quantit
trait
loci
qtl
identifi
within
haplotyp
control
persist
gener
good
correl
inbr
strain
suscept
three
phenotyp
viral
load
patholog
symptom
suggest
variat
demyelin
clinic
diseas
may
result
mous
strain
control
viral
load
persist
infect
use
congen
recombin
strain
mice
suscept
diseas
map
region
furthermor
resist
haplotyp
domin
locu
control
viral
load
persist
demyelin
current
suscept
loci
identifi
effect
suscept
theiler
virusinduc
diseas
tvid
see
tabl
mechan
tvid
may
differ
differ
mous
strain
inform
come
studi
sjlj
mice
infect
da
bean
strain
viru
viru
infect
oligodendrocyt
result
demyelin
diseas
could
due
part
viru
kill
oligodendrocyt
directli
virusspecif
ctl
present
lesion
seri
experi
demonstr
demyelin
correl
presenc
cellmedi
respons
viral
epitop
cell
secret
cytokin
interferon
ifn
activ
microgli
cell
invad
monocyt
subsequ
secret
factor
tumor
necrosi
factor
tnf
thu
caus
bystand
demyelin
activ
macrophag
ingest
degrad
damag
myelin
autoantibodi
myelinspecif
cell
shown
sjlj
mice
sever
month
intracrani
inocul
epitop
spread
mice
commenc
recognit
proteolipid
protein
plp
epitop
progress
addit
plp
epitop
myeloid
basic
protein
mbp
epitop
direct
demonstr
diseas
maintain
pure
autoimmun
foot
infect
erad
shown
immun
theiler
viru
first
respons
viral
infect
product
type
interferon
critic
viral
clearanc
receptor
knockout
mice
inject
tmev
die
encephalomyel
within
day
infect
nk
cell
activ
earli
infect
certain
virus
tmev
infect
suscept
sjl
mice
lower
nk
cell
activ
comparison
highli
resist
mice
low
nk
activ
sjl
mice
part
due
defect
thymu
impair
respons
nk
cell
stimul
pivot
role
nk
cell
earli
tmev
clearanc
demonstr
find
resist
mice
deplet
nk
cell
monoclon
antibodi
nk
develop
sever
sign
gray
matter
diseas
earli
diseas
cell
shown
import
viral
clearanc
earli
diseas
cell
requir
b
cell
produc
antibodi
viral
clearanc
cell
secret
vitro
inhibit
tmev
replic
protect
role
vivo
cell
also
import
viral
clearanc
demonstr
find
celldeplet
mice
fail
clear
viru
develop
sever
demyelin
diseas
cell
also
provid
protect
tvid
adopt
transfer
tvidsuscept
strain
balbcanncr
thu
cell
implic
viral
clearanc
resist
demyelin
higher
ctl
activ
demonstr
tvidresist
mice
compar
resist
sjlj
mice
ctl
may
play
import
role
viral
diseas
sinc
may
recogn
viral
determin
andor
may
inhibit
delay
type
hypersensit
respons
rel
role
cell
tvid
complex
simpl
pictur
polar
infect
may
appar
pathogen
role
cell
late
demyelin
diseas
demonstr
find
tvid
correl
delay
type
hypersensit
respons
tmev
deplet
cell
late
diseas
result
amelior
clinic
sign
high
level
proinfl
ammatori
cytokin
late
diseas
correl
well
maxim
diseas
activ
evid
demonstr
protect
role
tvid
shown
experi
skew
immun
respons
toward
immun
tmev
infect
diminish
later
demyelin
diseas
howev
studi
shown
balanc
explain
differ
suscept
tvid
cytokin
gener
pathogen
late
demyelin
diseas
wherea
cytokin
protect
character
abnorm
thin
myelin
sheath
relat
axon
diamet
date
howev
reliabl
data
frequenc
remyelin
ms
patient
stimul
remyelin
potenti
treatment
ms
tmev
model
ms
use
studi
remyelin
use
remyelinationpromot
antibodi
remyelin
model
sjlj
mice
age
week
inject
volum
contain
pfu
daniel
strain
intracerebr
anim
develop
mild
enceph
resolv
within
day
inject
infect
mice
develop
chronic
demyelin
diseas
gradual
progress
sever
month
studi
remyelin
mice
infect
tmev
month
receiv
singl
intraperiton
inject
mg
gkg
bodi
weight
recombin
remyelin
antibodi
phosphat
buffer
salin
pb
one
studi
lesion
anim
treat
show
retract
vari
degre
presum
effect
remyelin
lesion
direct
bind
demyelin
lesion
consist
hypothesi
antibodi
work
directli
lesion
probabl
bind
cn
glia
induc
remyelin
thu
murin
tmev
model
also
use
model
examin
differ
mode
remyelin
mous
hepat
viru
mhv
member
coronavirida
group
larg
posit
sens
envelop
rna
virus
depend
strain
viru
use
mhv
caus
varieti
diseas
includ
enter
hepat
demyelin
encephalomyel
infect
mice
neutrotrop
jhm
strain
mhv
caus
enceph
follow
chronic
demyelin
viru
clear
cn
result
persist
infect
intracerebr
intranas
infect
mhv
viru
enter
brain
caus
enceph
intranas
infect
mhvjhm
lead
viral
spread
olfactori
bulb
along
olfactori
tract
well
along
trigemin
nerv
mesencephal
nucleu
day
postinfect
pi
earli
viral
spread
via
specif
neural
pathway
neural
connect
viral
titer
peak
day
pi
brain
later
spinal
cord
viru
clear
day
pi
howev
viral
antigen
still
detect
day
pi
addit
viral
rna
detect
brain
late
month
postinfect
although
amount
rna
decreas
time
liver
infect
occur
rout
infect
ic
ig
ip
viral
titer
peak
day
pi
hepat
develop
first
week
cn
demyelin
develop
activ
mhv
infect
resolv
lesion
observ
histolog
similar
observ
ms
patient
mhv
lesion
character
primari
demyelin
accompani
nake
axon
found
scatter
throughout
spinal
cord
peripher
nervou
system
affect
chronic
lesion
associ
lipidladen
macrophag
scatter
lymphocyt
perivascular
cuf
chronic
lesion
persist
late
day
pi
demyelin
axon
seen
late
month
postinfect
chronic
diseas
mhvinfect
mice
associ
ataxia
hindlimb
paresi
paralysi
follow
recoveri
anim
recoveri
mediat
cn
remyelin
begin
anywher
day
pi
mice
b
suscept
mhv
infect
murin
model
adult
mice
weight
g
anesthet
inhal
anesthesia
receiv
intracerebr
inject
approxim
pfu
neurotrop
mhv
strain
volum
approxim
pb
intracerebr
inject
mhv
result
biphas
diseas
acut
encephalomyel
myelin
loss
follow
day
later
immunemedi
demyelin
encephalomyel
progress
destruct
cn
surviv
rate
mice
inject
mhv
anim
usual
succumb
first
week
acut
infect
anim
surviv
acut
stage
show
chanc
surviv
control
anim
inject
intracerebr
steril
pb
show
clinic
sign
histolog
defect
electron
micrograph
demyelin
lesion
show
macrophag
process
slip
layer
myelin
sheath
impli
macrophag
could
inde
mediat
demyelin
appear
macrophag
within
cn
also
correl
develop
lesion
addit
appear
larg
number
absenc
lymphocyt
possibl
myelin
damag
caus
nonmacrophagedepend
mechan
macrophag
may
clear
damag
myelin
contrast
mous
model
demyelin
appear
clear
role
singl
lymphocyt
monocyt
subset
mediat
demyelin
rather
appear
balanc
immun
compon
may
necessari
viral
clearanc
variou
pathway
immun
nonimmun
may
caus
ensu
demyelin
event
recent
progress
made
identifi
immun
cell
requir
demyelin
experiment
infect
sever
combin
immunodefici
scid
mice
lack
cell
result
fulmin
enceph
without
demyelin
adopt
transfer
splenocyt
syngen
immunocompet
mice
infect
scid
mice
result
demyelin
within
day
posttransf
addit
experi
indic
either
cell
subset
capabl
initi
process
howev
mice
receiv
splenocyt
deplet
cell
surviv
longer
develop
demyelin
mice
receiv
splenocyt
deplet
cell
thu
experiment
scid
mice
demonstr
role
cell
subset
demyelin
diseas
equal
critic
mediat
homeostasi
infl
ammat
ms
mani
rodent
model
bone
marrow
chimera
mice
use
address
role
bystand
demyelin
mediat
cell
chimera
rodent
model
jhm
address
hypothesi
produc
cell
sourc
critic
compon
mediat
bystand
demyelin
chimer
approach
compromis
product
cell
nk
cell
dendrit
cell
thu
preserv
innat
immun
respons
viru
result
demonstr
produc
innat
cell
unabl
initi
demyelin
diseas
even
context
activ
cell
lack
abil
produc
find
highlight
role
cell
demyelin
jmhinfect
mice
demonstr
critic
anim
model
demyelin
ms
semliki
forest
viru
sfv
alphaviru
togavirida
viru
isol
mosquito
natur
host
unknown
sfv
singlestrand
posit
strand
rna
viru
clone
sequenc
commonli
studi
strain
use
adult
mice
virul
strain
avirul
strain
strain
avirul
neonat
suckl
mice
rout
infect
experiment
infect
mice
sfv
wide
use
model
studi
mechan
virusinduc
cn
diseas
sfv
advantag
neuroinvas
well
neurotrop
thu
allow
studi
viral
entri
cn
integr
bloodbrain
barrier
bbb
follow
intraperiton
inject
pfu
sfv
ml
pb
contain
bovin
serum
albumin
strain
replic
muscl
tissu
result
plasma
viremia
viru
cross
cerebr
vascular
endotheli
cell
result
infect
neuron
oligodendrocyt
neonat
adult
mice
infect
virul
strain
result
widespread
infect
lethal
within
day
contrast
infect
mice
strain
result
cn
infect
infecti
viru
clear
brain
day
infiltr
mononuclear
cell
observ
day
pi
peak
day
focal
lesion
demyelin
throughout
cn
observ
day
pi
peak
day
pi
sfvinduc
demyelin
diseas
wide
studi
follow
intraperiton
inject
adult
mice
strain
viru
follow
intraperiton
inject
viru
detect
brain
h
viral
titer
rise
rapidli
declin
follow
initi
immun
respons
interestingli
although
infecti
viru
detect
day
pi
realtim
polymeras
chain
reaction
rtpcr
studi
detect
viral
rna
day
pi
thu
possibl
persist
viral
antigen
disturb
bbb
occur
day
pi
correspond
increas
inflammatori
cell
infi
ltration
reduct
viral
titer
may
relat
influx
cell
cytokinemedi
effect
presenc
macrophag
activ
microglia
proinfl
ammatori
cytokin
interleukin
il
granulocytemacrophag
colonystimul
factor
gmcsf
sfvinduc
demyelin
addit
enhanc
infl
ammatori
respons
may
also
play
role
control
viral
infect
sinc
tnf
direct
antivir
activ
addit
tnf
product
peripher
coincid
sfvinduc
enceph
sjl
mice
interestingli
cytokin
predomin
ms
lesion
intens
inflammatori
respons
character
perivascular
cuffi
ng
appar
histolog
day
demyelin
demonstr
use
luxol
fast
blue
stain
section
appar
day
howev
small
focal
lesion
demyelin
observ
use
electron
microscopi
day
strike
featur
sfv
infect
appear
optic
nerv
demyelin
lesion
chang
visual
evok
respons
axon
transport
optic
neuriti
also
occur
human
ms
appear
sfvinduc
demyelin
mous
model
accompani
neurophysiolog
demonstr
visual
deficit
similar
found
ms
patient
thu
may
provid
use
anim
model
research
ms
advantag
model
genet
environment
factor
readili
control
low
cost
fast
reproduct
rate
make
experiment
design
consider
easier
demyelin
observ
follow
sfv
infect
scid
mice
athym
mice
absenc
specif
immun
respons
scid
mice
infect
sfv
persist
viremia
persist
restrict
cn
infect
lesion
demyelin
comparison
infect
nunu
balbc
mice
studi
transfer
immun
sera
show
immunoglobulin
igm
antibodi
clear
viremia
brain
viru
infect
brain
viru
reduc
igg
antibodi
igg
antibodi
abolish
infect
titer
brain
remov
viral
rna
adopt
cell
transfer
studi
administr
antibodi
demonstr
demyelin
follow
sfv
infect
depend
cell
consist
find
cn
inflammatori
infiltr
domin
cell
fi
nding
analog
ms
contrast
eae
cell
predomin
eae
autoimmun
model
ms
studi
suggest
cytokin
profil
predomin
anoth
point
differ
eae
model
sfv
model
shown
profil
follow
infect
sfv
cytokin
detect
cn
present
throughout
time
cours
studi
indic
bia
th
respons
cn
chang
appar
time
experiment
diseas
eae
investig
mani
strain
anim
includ
mice
rat
guinea
pig
rabbit
marmoset
rhesu
monkey
eae
autoimmun
infl
ammatori
diseas
cn
character
perivascular
subpial
inflammatori
infiltr
demyelin
lesion
diseas
usual
initi
inject
autoantigen
emulsifi
ed
adjuv
progress
patholog
lesion
observ
depend
type
antigen
use
inject
method
inject
strain
anim
use
natur
eae
model
ms
address
certain
pertin
question
relat
ms
agerel
onset
diseas
epidemiolog
major
differ
eae
viral
model
ms
eae
inflammatori
respons
direct
autoantigen
featur
eae
model
cours
diseas
relaps
remit
studi
eae
use
identifi
antigen
determin
compon
myelin
use
bioinformat
technolog
determin
use
search
avail
databas
viral
bacteri
protein
result
indic
numer
viral
bacteri
protein
segment
probabl
sequenc
similar
myelin
basic
protein
determin
experiment
allerg
encephalomyel
rabbit
eae
induc
rabbit
footpad
inocul
rabbit
spinal
cord
homogen
result
hindlimb
paresi
paralysi
rabbit
paraplegia
show
increas
spinal
cord
incorpor
radioact
drug
administ
epidur
space
thu
demyelin
diseas
process
may
expos
spinal
cord
larger
amount
substanc
administ
neuraxi
therefor
possibl
rabbit
model
could
use
investig
incorpor
radioact
therapeut
drug
epidur
space
experiment
allerg
encephalomyel
guinea
pig
guinea
pig
also
investig
determin
whether
may
serv
use
eae
model
ms
interest
guinea
pig
stem
fact
group
glycoprotein
homologu
human
present
foreign
self
lipid
glycolipid
antigen
cell
found
mice
rat
present
guinea
pig
guinea
pig
model
anim
sensit
eae
mhc
class
ii
express
measur
cn
normal
guinea
pig
low
level
mhc
class
ii
occur
mening
macrophag
microgli
cell
wherea
immunoreact
absent
eae
cn
howev
major
infiltr
cell
mhc
ii
microglia
show
increas
express
wherea
immunoreact
detect
astrocyt
b
cell
macrophag
minim
mhc
ii
coexpress
detect
inflammatori
cell
glia
thu
guinea
pig
eae
model
group
molecul
upregul
cn
subset
cell
distinct
major
mhc
iibear
cell
express
protein
eae
lesion
broaden
potenti
repertoir
antigen
recogn
site
highlight
valu
guinea
pig
model
human
ms
experiment
allerg
encephalomyel
rat
rat
inject
spinal
cord
homogen
encephalitogen
myelin
basic
protein
induc
eae
genet
suscept
dark
agouti
da
rat
albino
oxford
ao
rat
rat
immun
either
hind
footpad
ml
antigen
emuls
contain
rat
spinal
cord
tissu
complet
freund
adjuv
cfa
rat
monitor
day
inocul
sever
diseas
assess
grade
tail
hindlimb
forelimb
weak
sale
diseas
loss
tail
tonic
hindlimb
weak
hindlimb
paralysi
moribund
dead
clinic
diseas
suscept
strain
rat
appar
anim
onset
diseas
occur
day
postinject
peak
clinic
manifest
eae
mark
increas
level
infiltr
cell
accompani
lack
activ
suscept
da
rat
wherea
remain
elev
resist
ao
rat
peak
clinic
diseas
da
rat
spinal
cord
contain
high
level
cell
da
rat
also
contain
time
mani
live
cell
ao
rat
astrocytosi
indic
cn
reaction
presenc
infl
ammatori
cell
clearli
observ
rat
speci
microgli
activ
persist
resist
ao
rat
wherea
activ
downregul
da
rat
model
specul
peak
diseas
infiltr
monocyt
macrophag
main
antigenpres
effector
cell
rat
eae
may
also
induc
inject
xenogen
myelin
exampl
lewi
rat
inject
hind
footpad
emuls
contain
guinea
pig
myelin
basic
protein
cfa
develop
acut
eae
also
chronic
relaps
eae
creae
may
also
induc
rat
model
use
regimen
intraperiton
inject
mgkg
cyclosporin
patholog
studi
indic
acut
creae
receptor
significantli
upregul
throughout
cours
creae
larg
number
macrophag
infiltr
creae
lesion
suggest
macrophag
recruit
cn
cell
respons
develop
relaps
eae
thu
rat
model
addit
cell
macrophag
anoth
target
immunotherapi
studi
neurolog
autoimmun
diseas
recent
develop
rat
eae
model
involv
use
human
mbp
antigen
eae
induc
immun
femal
wistar
rat
human
mbp
found
rat
develop
tail
tone
loss
hindlimb
paralysi
togeth
demyelin
infiltr
lymphocyt
foci
neurophagia
cortex
cerebra
white
matter
spinal
cord
studi
demonstr
rat
model
eae
induc
human
mbp
resembl
mani
featur
human
ms
may
promis
better
anim
model
studi
ms
use
cfa
prerequisit
develop
rat
eae
exampl
eae
induc
da
rat
singl
hind
footpad
inject
encephalitogen
emuls
consist
rat
guinea
pig
spinal
cord
homogen
sch
pb
reason
want
use
cfa
induc
strong
inflammatori
respons
exert
numer
immunomodulatori
properti
addit
cfa
induc
strong
antipurifi
protein
deriv
ppd
respons
may
induc
adjuv
arthriti
anoth
autoimmun
diseas
suscept
da
rat
eae
induct
sch
depend
upon
origin
cn
tissu
homolog
tissu
effici
encephalitogen
da
rat
recov
eae
induc
homolog
sch
without
adjuv
immun
encephalitogen
emuls
contain
cfa
develop
clinic
sign
diseas
neurolog
sign
rechalleng
rat
milder
first
sign
appear
earlier
earlier
onset
eae
observ
da
rat
rechalleng
attribut
reactiv
memori
cell
taken
togeth
experi
demonstr
eae
effi
cientli
reproduc
induc
da
rat
without
use
cfa
experiment
model
understand
basic
mechan
involv
autoimmun
within
cn
without
limit
inher
problem
impos
applic
adjuv
may
repres
one
reliabl
rodent
model
ms
rat
experiment
model
could
use
evalu
new
immunotherapi
eae
includ
antigeninduc
mucos
toler
treatment
cytokin
dendrit
cellbas
immunotherapi
ideal
treatment
diseas
autoimmun
background
ms
specif
elimin
autoreact
cell
without
affect
integr
immun
system
one
way
achiev
would
induc
immunolog
toler
autoantigen
oral
nasal
administr
autoantigen
sever
studi
shown
nasal
administr
solubl
antigen
result
peripher
toler
immun
deviat
induct
regulatori
mechan
rat
model
toler
investig
use
synthet
peptid
mbp
nasal
administr
encephalitogen
suppress
eae
given
togeth
synergist
effect
suppress
eae
revers
ongo
eae
problem
howev
antigenspecif
therapi
nasal
rout
one
antigen
peptid
may
effect
induc
toler
one
strain
anim
anoth
one
way
treat
ongo
eae
may
use
alter
peptid
ligand
high
tolerogen
efficaci
administ
nasal
cytokin
wide
use
diseas
prevent
treatment
cytokin
immunotherapi
ms
could
employ
one
two
basic
strategi
first
administ
immun
respons
downregulatori
cytokin
second
administ
inhibitor
proinfl
ammatori
cytokin
nasal
rout
administ
cytokin
studi
rat
eae
model
nasal
administr
low
dose
antiinflammatori
regulatori
cytokin
tumor
growth
factor
tgf
inhibit
develop
rat
eae
given
day
immun
differ
mechan
nasal
administ
reduc
peripher
immun
respons
microglia
activ
cn
wherea
nasal
administr
trigger
activ
dendrit
cell
dc
howev
nasal
administr
cytokin
alon
fail
treat
ongo
lewi
rat
eae
interestingli
nasal
administr
suppress
ongo
eae
lewi
rat
suppress
eae
associ
induct
broad
lymphocyt
hyporespons
although
combin
administr
autoantigen
plu
cytokin
may
effect
treat
rat
eae
applic
human
ms
sever
limit
lack
knowledg
patholog
relev
autoantigen
ms
dc
activ
lymphocyt
also
induc
cell
toler
antigen
use
tolerogen
dc
thu
possibl
immunotherapeut
strategi
treatment
eae
inde
studi
detail
howev
dc
prevent
develop
eae
fail
treat
ongo
eae
lewi
rat
attempt
treat
ongo
eae
splenic
dc
isol
healthi
lewi
rat
modifi
ed
vitro
cytokin
upon
subcutan
inject
lewi
rat
day
pi
fca
ed
dc
promot
immun
protect
eae
common
marmoset
callithrix
jacchu
outbr
speci
character
natur
occur
bone
marrow
chimer
marmoset
primat
phylogenet
close
human
studi
anim
model
ms
eae
induc
common
marmoset
inject
human
brain
white
matter
dispers
deminer
water
concentr
mgml
emulsifi
cfa
contain
mgml
mycobacterium
butyricum
monkey
inject
intracutan
emuls
dorsal
skin
sever
locat
clinic
diseas
model
score
daili
scale
clinic
sign
apathi
loss
appetit
alter
walk
pattern
without
ataxia
lethargi
andor
anorexia
ataxia
paraparesi
monoparesi
andor
sensori
loss
andor
brainstem
syndrom
paraplegia
hemiplegia
quadriplegia
spontan
death
attribut
eae
onset
diseas
measur
clinic
score
variabl
among
anim
week
postinocul
addit
maxim
clinic
score
variabl
among
anim
rang
histopatholog
examin
larg
plaqu
demyelin
observ
white
matter
cerebr
hemispher
mainli
local
around
wall
later
ventricl
hemispher
white
matter
corpu
callosum
optic
nerv
optic
tract
demyelin
area
show
moder
sever
degre
inflamm
character
perivascular
cuff
mononuclear
cell
spinal
cord
widespread
demyelin
also
observ
area
demyelin
involv
ventral
later
dorsal
column
spinal
cord
especi
outer
part
spinal
tract
thu
patholog
marmoset
model
character
infl
ammat
demyelin
astrogliosi
interestingli
model
demonstr
presenc
axon
damag
demyelin
plaqu
inde
axon
damag
loss
wellknown
event
ms
ms
axon
damag
appear
earli
event
relat
acut
inflamm
marmoset
eae
axon
damag
also
occur
area
acut
earli
inflamm
demyelin
eae
c
jacchu
special
interest
resembl
model
human
diseas
similar
immun
system
marmoset
human
type
clinic
sign
eae
marmoset
depend
larg
antigen
use
diseas
induct
sensit
marmoset
human
myelin
induc
relapsingremit
secondaryprogress
diseas
cours
lesion
model
repres
stage
present
chronic
ms
marmoset
inocul
mbp
develop
mild
inflammatori
diseas
unless
bordetella
pertussi
use
encephalitogen
cn
demyelin
critic
depend
presenc
antibodi
myelin
oligodendrocyt
glycoprotein
mog
minor
cn
compon
marmoset
sensit
chimer
protein
mbp
proteolipid
protein
myelin
develop
clinic
eae
autoimmun
reaction
spread
mog
marmoset
immun
recombin
human
mog
develop
relapsingremit
diseas
chronicprogress
diseas
asymptomat
phase
primari
progressivelik
diseas
last
week
brain
lesion
detect
use
magnet
reson
imag
mri
express
clinic
induct
eae
mbp
white
matter
tissu
homogen
wmh
well
establish
rhesu
monkey
macaca
mulatta
rhesu
monkey
first
anim
speci
eae
deliber
induc
autoimmun
brain
antigen
could
induc
paralyt
diseas
confirm
studi
rhesu
monkey
given
repeat
inocul
brain
homogen
moginduc
eae
also
produc
nonhuman
primat
speci
highli
relev
model
human
diseas
close
similar
human
rhesu
monkey
immun
system
illustr
high
degre
similar
polymorph
mhc
cell
receptor
gene
two
primat
produc
moginduc
eae
monkey
inject
anesthesia
total
ml
emuls
compos
mog
pb
cfa
site
dorsal
skin
overt
clinic
sign
score
daili
accord
follow
criteria
clinic
sign
loss
appetit
apathi
alter
walk
lethargi
anorexia
substanti
reduct
gener
condit
loss
tail
tonu
ataxia
tail
bite
sensori
loss
andor
blind
incomplet
paralysi
one
hemiparesi
two
side
paraparesi
complet
paralysi
one
hemiplegia
two
side
paraplegia
complet
paralysi
quadriplegia
death
onset
clinic
diseas
vari
anim
occur
day
encephalitogen
challeng
monkey
howev
develop
clinic
diseas
achiev
score
clinic
sever
current
avail
panel
nonhuman
primat
eae
model
may
reflect
spectrum
inflammatori
demyelin
diseas
human
popul
eae
model
therefor
use
investig
pathogen
mechan
develop
effect
therapi
wide
studi
anim
model
eae
mous
common
anim
model
eae
diseas
induct
vari
depend
sex
anim
mous
strain
use
well
origin
spinal
cord
encephalitogen
model
mice
age
week
immun
subcutan
four
site
back
guinea
pig
mbp
emulsifi
equal
volum
cfa
contain
heatkil
mycobacterium
tuberculosi
mice
also
receiv
pertussi
toxin
ml
pb
intraperiton
time
immun
h
later
mice
score
daili
clinic
sign
eae
least
day
follow
clinic
sign
limp
tail
waddl
gait
tail
tonic
ataxia
waddl
gait
tail
limp
partial
hindlimb
paralysi
total
hindlimb
paralysi
moribunddeath
strain
mice
variat
day
onset
diseas
vari
day
day
postinfect
incid
diseas
vari
anim
incid
mortal
vari
anim
mean
clinic
score
vari
mani
mous
strain
employ
studi
eae
sjl
strain
frequent
use
model
gender
differ
diseas
onset
sever
sjl
model
limit
due
diminish
cell
repertoir
certain
suscept
strain
mice
fvb
mice
show
relapsingremit
cours
diseas
bear
resembl
ms
fvb
mice
therefor
may
serv
mous
strain
variou
transgen
may
introduc
purpos
studi
influenc
eae
explor
new
therapeut
approach
sinc
eae
wellstudi
diseas
mice
mimick
mani
clinic
patholog
featur
ms
includ
cn
infl
ammat
demyelin
signific
also
use
appropri
model
studi
msrelat
pain
clearli
demonstr
sjl
activ
passiv
eae
initi
increas
tail
withdraw
latenc
hypoalgesia
peak
sever
day
prior
peak
motor
defi
cit
acut
diseas
phase
chronic
diseas
phase
tail
withdraw
latenc
decreas
significantli
faster
control
latenc
day
postimmun
thu
possibl
use
murin
activ
passiv
eae
model
msrelat
pain
specif
immunotherapeut
strategi
effect
experiment
model
system
translat
human
diseas
genet
poorli
toler
prove
ineffect
conflict
may
part
due
model
system
use
well
poor
correl
vitro
find
compar
observ
vivo
biozzi
abh
mice
express
novel
mhc
class
ii
eae
occur
follow
immun
myelin
protein
peptid
epitop
protein
howev
plp
peptid
mog
peptid
spinal
cord
homogen
reproduc
induc
chronic
relaps
eae
creae
infl
ammat
demyelin
creae
provid
wellcharacter
reproduc
system
develop
therapeut
strategi
establish
relaps
autoimmun
neurolog
diseas
pertin
ms
creae
abh
mice
relaps
progress
diseas
associ
emerg
broaden
immun
repertoir
due
releas
myelin
antigen
follow
myelin
damag
thu
creae
model
biozzi
abh
mice
well
suit
model
examin
effect
therapeut
strategi
dynam
system
diseas
suscept
human
ms
associ
three
mhc
class
ii
allel
haplotyp
autoimmun
pathogenesi
hypothes
one
mhc
class
ii
molecul
present
cnsderiv
selfantigen
autoaggress
cell
infiltr
cn
initi
infl
ammatori
respons
howev
target
autoantigen
ms
unknown
immun
mice
myelin
brainassoci
protein
induc
eae
diseas
resembl
ms
clinic
patholog
protein
mbp
plp
mog
compon
myelin
sheath
candid
antigen
inde
cell
reactiv
antigen
demonstr
ms
patient
mice
express
human
molecul
capabl
present
peptid
three
ms
candid
autoantigen
possibl
ms
cell
respond
one
antigen
may
initi
diseas
epitop
spread
recruit
cell
addit
specif
diseas
progress
could
lead
infl
ammatori
respons
sever
protein
result
escal
autoimmun
respons
transgen
mous
model
multipl
sclerosi
well
establish
follow
two
exampl
transgen
model
first
ms
associ
hla
class
ii
molecul
human
difficult
analyz
individu
role
hla
molecul
diseas
pathogenesi
due
heterogen
mhc
gene
linkag
disequilibrium
influenc
nonmhc
gene
contribut
environment
factor
howev
specif
role
class
ii
molecul
address
use
transgen
model
express
hla
gene
model
could
prove
use
deciph
role
hla
molecul
autoantigen
ms
second
eae
valuabl
model
immunopathogenesi
ms
sometim
difficult
reconcil
fi
nding
therapi
rodent
model
cellular
molecular
interact
studi
human
diseas
human
transgen
mice
offer
mean
achiev
express
diseaseimpl
hla
class
ii
molecul
coexpress
cognat
hlaclass
iirestrict
myelinspecifi
c
cell
receptor
deriv
human
cell
clone
implic
diseas
transgen
mice
could
provid
excel
model
studi
epitop
spread
human
immunogenet
environ
test
immunotherapi
major
current
therapi
plan
phase
ii
iii
trial
ms
first
examin
eae
thu
particularli
pertin
question
whether
eae
suitabl
relev
research
tool
ms
research
believ
eae
use
model
acut
human
cn
demyelin
contribut
understand
ms
limit
eae
acut
monophas
ill
compar
ms
chronic
relaps
diseas
may
suit
model
acut
dissemin
encephalomyel
adem
drawback
eae
model
includ
follow
natur
inflammatori
respons
eae
compar
ms
diseas
eae
compar
ms
differ
patholog
eae
ms
pitfal
extend
immunotherapi
eae
ms
see
tabl
consequ
may
conclud
clinic
pictur
eae
present
depend
anim
speci
use
also
rout
administr
encephalitogen
natur
encephalitogen
mbp
plp
mog
thu
possibl
eae
model
somewhat
imprecis
method
studi
pathogenesi
ms
develop
therapeut
strategi
nonhuman
primat
eae
model
primari
import
safeti
efficaci
test
new
therapeut
ms
may
work
suffici
well
speci
distant
human
rodent
question
concern
immunogen
biolog
therapeut
also
address
nonhuman
primat
mani
biolog
therapeut
antibodi
alter
peptid
ligand
investig
rodent
although
therapeut
effect
treat
eae
rodent
proven
partial
effect
case
detriment
ms
patient
ultim
rais
question
whether
rodent
model
appropri
anim
model
test
new
therapeut
strategi
use
human
ms
sever
exampl
human
anim
demyelin
diseas
associ
viral
infect
demyelin
associ
vitamin
defici
toxin
mani
differ
anim
model
eae
studi
use
variou
mri
techniqu
clinic
featur
model
depend
greatli
upon
rout
inocul
encephalitogen
well
speci
strain
anim
use
inocul
rout
subcutan
footpad
intraperiton
help
determin
onset
locat
lesion
brain
spinal
cord
thu
creat
demyelin
lesion
precis
known
locat
time
cours
stereotax
techniqu
use
inocul
anim
chemic
induc
demyelin
lesion
brain
sever
chemic
ethidium
bromid
cuprizon
lysophosphatidylcholin
lpc
inject
directli
nerv
cn
produc
lesion
demyelin
demyelin
studi
lpc
male
wistar
rat
anesthet
sodium
pentath
fix
rat
head
restrain
stereotax
surgic
tabl
head
shave
burr
hole
creat
lpc
solut
isoton
salin
inject
use
injector
cannula
lpc
infus
rate
next
min
cannula
remov
burr
hole
close
use
bone
wax
rat
observ
daili
histolog
studi
carri
day
day
lpc
inject
cover
entir
process
diseas
evolut
use
lpcinduc
demyelin
possibl
observ
complet
patholog
process
demyelin
remyelin
anim
model
ms
demyelin
observ
maximum
valu
occur
day
day
remyelin
start
reduct
edema
model
could
particularli
use
studi
remyelin
one
promin
featur
chemic
induc
lesion
demyelin
lesion
subsequ
remyelin
studi
without
interfer
immun
mechan
tremend
advantag
viral
induc
model
ms
sinc
viru
inocul
none
remain
affect
remyelin
